ProQinase Information

ProQinase is a leading contract research company for cancer drug discovery. The company has a long-standing scientific experience in cancer research with a focus on protein kinases and tumor angiogenesis. Currently 301 in-house produced catalytically active protein kinases, 15 lipid kinases and 14 kinase substrates are offered for sale. Furthermore, 413 protein kinases and 17 lipid kinases are available for biochemical kinase assay services (HTS, selectivity profiling and IC50 determination). Hits derived from biochemical kinase assays can be further characterized at ProQinase in cell-based, target-specific phosphorylation assays and in various functional cell-based assays like 3D tumor spheroid assays, migration assays, proliferation assays, soft agar assays, and angiogenesis assays. ProQinase’s portfolio of preclinical services is completed by in vivo testing services including subcutaneous tumor models (xenograft tumor models), orthotopic tumor models with in vivo and ex vivo bioluminescence analysis and a unique in vivo angiogenesis assay. With our new syngeneic platform we are able to characterize the subsets of tumor infiltrating immune cells. In addition, ProQinase provides custom-tailored solutions of preclinical services as support for cancer drug discovery projects.